The AQP3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line, in which AQP3 gene function has been disrupted. This polyclonal model provides a heterogeneous pool of gene-edited cells, enabling robust loss-of-function studies without the clonal biases of single-cell isolates.
The A-549 cell line, originating from alveolar basal epithelial cells, serves as a widely used model for pulmonary epithelial biology, surfactant production, and non-small cell lung cancer. Its adherent morphology and type II pneumocyte characteristics make it suitable for investigating airway physiology and tumorigenic mechanisms.
AQP3 encodes an aquaglyceroporin facilitating transmembrane transport of water, glycerol, urea, and hydrogen peroxide. In A-549 cells, AQP3 is regulated by upstream factors such as EGF, corticosteroids, and TNF-alpha, and interacts with ezrin, the actin cytoskeleton, and lipid raft components including caveolin-1. Glycerol influx via AQP3 supports ATP production and engages the EGFR?CRas?CRaf1?CMEK1?CMAPK3/1 (ERK) cascade, enhancing ERK phosphorylation and cofilin activation to promote cell migration and proliferation.
Disruption of AQP3 in this background abolishes glycerol and water transport, impairing cell migration and proliferation likely through diminished ERK signaling and energy metabolism, thereby reducing tumorigenic potential. This polyclonal knockout population provides a physiologically relevant model to dissect AQP3-dependent contributions to lung adenocarcinoma progression and EGFR-driven pathways.
Researchers can employ these cells in wound healing, transwell migration, glycerol uptake, and immunofluorescence assays, as well as western blotting for AQP3 and phospho-ERK and MTT proliferation assays. They are also suitable for drug screening targeting AQP3-mediated mechanisms in lung adenocarcinoma. For further information, please contact Ascent Research.
